Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bhatt, Kunjan
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
HF2 Registry, NCT06425848: - Hemodynamic Frontiers in Heart Failure Registry	Recruiting	N/A	2000	US	Observational	University of Kansas Medical Center	Heart Failure	12/30	12/30
FUTURE-HF2, NCT05763407: Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)	Recruiting	N/A	25	US	FIRE1 System	Foundry Innovation & Research 1, Limited (FIRE1)	Heart Failure	04/25	01/26
NCT04600791: BATwire Implant Kit	Terminated	N/A	93	US	BATwire Implant Kit	CVRx, Inc.	Heart Failure	08/24	02/25
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)	Active, not recruiting	N/A	5000	US	Barostim™ System	CVRx, Inc.	Heart Failure	06/28	06/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bhatt, Kunjan
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
HF2 Registry, NCT06425848: - Hemodynamic Frontiers in Heart Failure Registry	Recruiting	N/A	2000	US	Observational	University of Kansas Medical Center	Heart Failure	12/30	12/30
FUTURE-HF2, NCT05763407: Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)	Recruiting	N/A	25	US	FIRE1 System	Foundry Innovation & Research 1, Limited (FIRE1)	Heart Failure	04/25	01/26
NCT04600791: BATwire Implant Kit	Terminated	N/A	93	US	BATwire Implant Kit	CVRx, Inc.	Heart Failure	08/24	02/25
NCT04502316: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)	Active, not recruiting	N/A	5000	US	Barostim™ System	CVRx, Inc.	Heart Failure	06/28	06/28